What tirzepatide does to your liver enzymes — and what the evidence shows

The misconception: that tirzepatide damages your liver

A question our prescribers hear most weeks runs roughly like this: 'I've heard these injections can harm your liver, should I be getting blood tests?' It is a fair concern, and not an unreasonable one given how widely GLP-1 medicines are discussed online. The short answer is that the evidence points in the opposite direction for most people.

In the SURMOUNT-1 trial (which enrolled over 2,500 adults with obesity) participants treated with tirzepatide showed significant reductions in alanine aminotransferase (ALT), a standard marker of liver stress, compared with those on placebo. Similar patterns emerged across the SURMOUNT programme. This is not coincidental: tirzepatide drives meaningful fat loss, and fatty liver (metabolically associated steatotic liver disease, or MASLD) is closely tied to excess body weight. As weight falls, liver fat tends to fall with it, and enzyme levels often follow. The connection between tirzepatide and fatty liver is an active and genuinely encouraging area of research.

That does not mean liver enzymes cannot change on any medicine, they can, for all sorts of reasons unrelated to the treatment itself. The point is that tirzepatide has not been identified as a hepatotoxic drug. If you are curious about the specifics, our page on whether Mounjaro affects liver enzymes sets out what the evidence shows in plain terms. The NHS medicines information for tirzepatide does not list liver injury among its recognised adverse effects, and the European and UK regulators reviewed the full trial safety dataset before granting authorisation. You can read the NHS tirzepatide medicines page for the full side-effect profile.

What the trial data actually measured, and what it did not

It is worth being precise here, because 'liver enzymes' covers a range of markers. Most of the available data focuses on ALT and AST, both of which reflect hepatocyte stress. Improvements in these values in the tirzepatide arms of trials are well-documented and appear to correlate with the degree of weight reduction achieved.

What the trials did not do is systematically enrol large numbers of people with advanced or decompensated liver disease. Most participants had metabolic risk factors, including fatty liver, but few had cirrhosis or portal hypertension. This means the evidence base for people with severe liver disease is thinner, and extrapolating the reassuring enzyme data to that group is not straightforward.

There is also the question of what happens at each dose increase. Tirzepatide is started at 2.5mg and titrated gradually, a schedule designed partly to reduce gastrointestinal side effects. Whether liver-enzyme trends persist across all dose levels in a real-world population is still being studied. For a fuller look at how tirzepatide interacts with liver health across different clinical situations, the page on tirzepatide and the liver covers the broader picture.

NICE's appraisal of tirzepatide, TA1026, reviewed the clinical evidence comprehensively before recommending it for use in England, including its safety profile across metabolic comorbidities.

When to involve your prescriber or specialist

For most people starting tirzepatide, liver enzymes are not a day-to-day concern. However, there are situations where involving a prescriber or hepatologist before and during treatment matters.

If you have a known liver condition (fatty liver disease, non-alcoholic steatohepatitis, or anything more advanced) tell your prescriber before starting. The implications of tirzepatide in liver disease depend heavily on severity. Mild-to-moderate fatty liver is very different from compensated cirrhosis, and decompensated liver disease is a situation that requires specialist input, full stop.

During treatment, contact your GP or prescriber if you notice yellowing of the skin or whites of the eyes, very dark urine, significant upper-right abdominal pain, or persistent fatigue that feels different from the ordinary tiredness some people report when starting the medicine. These symptoms are not common and are not expected side effects of tirzepatide, but they are the warning signs of liver stress that should never be waited out. You can report any suspected side effects to the MHRA via the Yellow Card scheme.

Alcohol is a separate but related consideration: even moderate regular drinking affects liver enzymes, and the interaction between alcohol and GLP-1 treatment is worth discussing with your prescriber. The page on drinking alcohol on Mounjaro covers what is currently known.

If you are ready to discuss your own situation with a clinician rather than reading further, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not automated software.